Skip to main content

As Expected, Ciphergen Sells Chromatography Business to Pall for $32M

NEW YORK, Dec. 1 (GenomeWeb News) - Ciphergen has sold its BioSepra process-chromatography business to Pall for roughly $32 million.

 

The initial agreement to sell the business was announced in late October. As reported by GenomeWeb News at the time, the firms also entered into a collaboration under which New York-based Pall will establish process proteomics service centers to offer protein purification using BioSepra's chromatography products and Ciphergen's ProteinChip technology.

 

Ciphergen also said that it will retain certain limited rights to access BioSepra's chromatography sorbent technology for use in research and diagnostic markets.

 

Ciphergen recently reported a 31-percent decline in third-quarter revenue as sales of its ProteinChip mass spectrometry systems and BioSepra process chromatography products took a hit. The firm's loss for the quarter grew to $9.5 million, or $.33 per share, from a loss of $5.2 million, or $.18 per share, in the third quarter of 2003.

 

According to ProteoMonitor, a GenomeWeb News publication, the company predicted fourth-quarter revenue of between $11 million and $13 million. Of that amount, between $9.5 million and $11.5 million will be revenues that do not include BioSepra.

 

"The sale of our BioSepra process chromatography business allows us to focus our financial and business resources on our core research products and emerging diagnostic business," William Rich, CEO of Ciphergen, said in a statement announcing the third-quarter results. "The joint sales and marketing collaboration with Pall Corporation positions us to continue to sell the Protein Chip Systems into the process proteomics market."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.